Panelists discuss emerging immunotherapy strategies for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), particularly the combination of BCG with systemic checkpoint inhibitors, noting ...

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...

The device was previously approved in March 2019 3 for patients with BPH with prostate volumes ranging from 30 cm 3 to 80 cm 3. Meta-analysis The approval is supported by several studies highlighting ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking ...

Key Takeaways Apalutamide showed a significant survival advantage over abiraterone and enzalutamide in mCSPC, with a 26% and 23% reduction in mortality risk, respectively. Real-world data are ...

The iSNM system is intended to provide an alternative to traditional SNM for these patients. According to Neuspera, “A smart, miniaturized neurostimulator is implanted near the sacral nerve, and ...

Diagnostic Performance of the ZIRCON Trial Main Discussion Topics: A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC) A 75% negative predictive value Important ...

Future Research Directions Key Themes: There is a need for continued efforts to improve minority enrollment in clinical trials. The importance of real-world evidence to complement trial data is ...

Molecular Imaging in Risk Stratification and Adjuvant Therapy Main Discussion Topics: Potential role in identifying patients appropriate for adjuvant pembrolizumab after nephrectomy Possible utility ...

Improving Clinical Trial Diversity Key Themes: A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building ...

Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic hyperplasia (BPH) is increasing among men aged 50 to 65. 1 Overall, MIST ...